Pulmonary Arterial Hypertension (PAH) - Market Insight, Epidemiology and Market Forecast - 2027

    Pulmonary Arterial Hypertension (PAH)  - Market Insight, Epidemiology and Market Forecast - 2027
    Date: 01 Jan, 2018
    Type: Pharmaceutical Industry Report
    Pages: 100
    Geography: Global
    Code: DIMI0017
    Delivery Timeline: 7-10 Business Days
    DelveInsight's "Pulmonary Arterial Hypertension (PAH) - Market Insight, Epidemiology and Market Forecast - 2027" report provides a detailed analysis of the Pulmonary Arterial Hypertension (PAH) epidemiology and market outlook for the 7MM.

    Markets Covered
    • United States
    • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
    • Japan

    Study Period: 2016-2027

    Pulmonary Arterial Hypertension (PAH) Understanding and Treatment Algorithm
    The market report provides the overview of the Pulmonary Arterial Hypertension (PAH) by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

    Pulmonary Arterial Hypertension (PAH) Epidemiology
    The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2018 to 2027 segmented by seven major markets, enabling to understand the potential of the Pulmonary Arterial Hypertension (PAH) in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

    Pulmonary Arterial Hypertension (PAH) Product Profiles & Analysis
    The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

    Pulmonary Arterial Hypertension (PAH) Market Outlook
    The report’s market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Pulmonary Arterial Hypertension (PAH) market.

    Pulmonary Arterial Hypertension (PAH) Market Share by Therapies
    This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2027. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

    Pulmonary Arterial Hypertension (PAH) Report Insights
    • Patient Population in Pulmonary Arterial Hypertension (PAH)
    • Therapeutic Approaches in Pulmonary Arterial Hypertension (PAH)
    • Pulmonary Arterial Hypertension (PAH) Pipeline Analysis
    • Pulmonary Arterial Hypertension (PAH) Market Size and Trends
    • Pulmonary Arterial Hypertension (PAH) Market Opportunities
    • Impact of upcoming Therapies in Pulmonary Arterial Hypertension (PAH)

    Pulmonary Arterial Hypertension (PAH) Report Key Strengths
    • 10 Year Forecast
    • 7MM Coverage
    • Epidemiology Segmentation
    • Drugs Uptake
    • Highly Analyzed Market
    • Key Cross Competition

    Pulmonary Arterial Hypertension (PAH) Report Assessment
    • Current Treatment Practices in Pulmonary Arterial Hypertension (PAH)
    • Unmet Needs in Pulmonary Arterial Hypertension (PAH)
    • Market Attractiveness
    • Market Drivers and Barriers

    Key Benefits
    • The report will help to develop Business Strategies by understanding the trends shaping and driving the Pulmonary Arterial Hypertension (PAH) market
    • Organize sales and marketing efforts by identifying the best opportunities for Pulmonary Arterial Hypertension (PAH) market
    • To understand the future market competition in the Pulmonary Arterial Hypertension (PAH) market.
    1. Report Introduction
    2. Pulmonary Arterial Hypertension (PAH) Market Overview at a Glance
    2.1. Market Share Distribution of Pulmonary Arterial Hypertension (PAH) in 2017
    2.2. Market Share Distribution of Pulmonary Arterial Hypertension (PAH) in 2027
    3. Disease Background and Overview: Pulmonary Arterial Hypertension (PAH)
    3.1. Introduction
    3.2. Symptoms
    3.3. Etiology
    3.4. Risk Factors
    3.5. Pathophysiology
    3.6. Diagnosis
    3.7. Treatment
    4. Epidemiology and Patient Population
    4.1. Key Findings
    4.2. Total Prevalent/ Incident Patient Population of Pulmonary Arterial Hypertension (PAH) in 7MM
    4.3. Total Prevalent Patient Population of Pulmonary Arterial Hypertension (PAH) in 7MM – By Countries
    5. Epidemiology of Pulmonary Arterial Hypertension (PAH) by Countries
    5.1. United States
    5.1.1. Assumptions and Rationale
    5.1.2. Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH)
    5.1.3. Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) *
    5.1.4. Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) *
    5.1.5. Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH)
    5.1.6. Treatable Cases of the Pulmonary Arterial Hypertension (PAH)
    5.2. EU5
    5.3. Assumptions and Rationale
    5.4. Germany
    5.4.1. Assumptions and Rationale
    5.4.2. Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH)
    5.4.3. Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) *
    5.4.4. Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) *
    5.4.5. Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH)
    5.4.6. Treatable Cases of the Pulmonary Arterial Hypertension (PAH)
    5.5. France
    5.5.1. Assumptions and Rationale
    5.5.2. Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH)
    5.5.3. Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) *
    5.5.4. Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) *
    5.5.5. Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH)
    5.5.6. Treatable Cases of the Pulmonary Arterial Hypertension (PAH)
    5.6. Italy
    5.6.1. Assumptions and Rationale
    5.6.2. Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH)
    5.6.3. Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) *
    5.6.4. Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) *
    5.6.5. Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH)
    5.6.6. Treatable Cases of the Pulmonary Arterial Hypertension (PAH)
    5.7. Spain
    5.7.1. Assumptions and Rationale
    5.7.2. Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH)
    5.7.3. Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) *
    5.7.4. Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) *
    5.7.5. Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH)
    5.7.6. Treatable Cases of the Pulmonary Arterial Hypertension (PAH)
    5.8. United Kingdom
    5.8.1. Assumptions and Rationale
    5.8.2. Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH)
    5.8.3. Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) *
    5.8.4. Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) *
    5.8.5. Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH)
    5.8.6. Treatable Cases of the Pulmonary Arterial Hypertension (PAH)
    5.9. Japan
    5.9.1. Assumptions and Rationale
    5.9.2. Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH)
    5.9.3. Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) *
    5.9.4. Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) *
    5.9.5. Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH)
    5.9.6. Treatable Cases of the Pulmonary Arterial Hypertension (PAH)
    6. Current Treatment & Medical practices
    6.1. Treatment Algorithm
    6.2. Treatment Guidelines
    7. Unmet Needs of the Pulmonary Arterial Hypertension (PAH)
    8. Marketed Therapies
    8.1. Drug A: Company 1
    8.1.1. Drug Description
    8.1.2. Mechanism of Action
    8.1.3. Regulatory Milestones
    8.1.4. Advantages & Disadvantages
    8.1.5. Product Profile
    8.2. Drug B: Company 2
    8.2.1. Drug Description
    8.2.2. Mechanism of Action
    8.2.3. Regulatory Milestones
    8.2.4. Advantages & Disadvantages
    8.2.5. Product Profile
    9. Pipeline Therapies – At a glance
    10. Key Cross Competition
    11. Emerging Therapies for Pulmonary Arterial Hypertension (PAH)
    11.1. Drug C: Company 3
    11.1.1. Drug Description
    11.1.2. Clinical Trials Details
    11.1.3. Safety and Efficacy Profile
    11.1.4. Advantages & Disadvantages
    11.1.5. Pipeline Development Activities
    11.1.6. Product Profile
    11.2. Drug D: Company 4
    11.2.1. Drug Description
    11.2.2. Clinical Trials Details
    11.2.3. Safety and Efficacy Profile
    11.2.4. Advantages & Disadvantages
    11.2.5. Pipeline Development Activities
    11.2.6. Product Profile
    12. Pulmonary Arterial Hypertension (PAH) : 7MM Market Analysis
    12.1. 7MM Market Size of Pulmonary Arterial Hypertension (PAH)
    12.2. 7MM Percentage Share of drugs marketed for Pulmonary Arterial Hypertension (PAH)
    12.3. 7MM Market Sales of Pulmonary Arterial Hypertension (PAH) by Products
    13. Pulmonary Arterial Hypertension (PAH) : Country-Wise Market Analysis
    13.1. United States
    13.1.1. Market Size of Pulmonary Arterial Hypertension (PAH) in United States
    13.1.2. Percentage Share of drugs marketed for Pulmonary Arterial Hypertension (PAH) in United States
    13.1.3. Market Sales of Pulmonary Arterial Hypertension (PAH) by Products in United States
    13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
    13.2. EU-5
    13.2.1. Germany
    13.2.1.1. Market Size of Pulmonary Arterial Hypertension (PAH) in Germany
    13.2.1.2. Percentage Share of drugs marketed for Pulmonary Arterial Hypertension (PAH) in Germany
    13.2.1.3. Market Sales of Pulmonary Arterial Hypertension (PAH) by Products in Germany
    13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
    13.2.2. France
    13.2.2.1. Market Size of Pulmonary Arterial Hypertension (PAH) in France
    13.2.2.2. Percentage Share of drugs marketed for Pulmonary Arterial Hypertension (PAH) in France
    13.2.2.3. Market Sales of Pulmonary Arterial Hypertension (PAH) by Products in France
    13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
    13.2.3. Italy
    13.2.3.1. Market Size of Pulmonary Arterial Hypertension (PAH) in Italy
    13.2.3.2. Percentage Share of drugs marketed for Pulmonary Arterial Hypertension (PAH) in Italy
    13.2.3.3. Market Sales of Pulmonary Arterial Hypertension (PAH) by Products in Italy
    13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
    13.2.4. Spain
    13.2.4.1. Market Size of Pulmonary Arterial Hypertension (PAH) in Spain
    13.2.4.2. Percentage Share of drugs marketed for Pulmonary Arterial Hypertension (PAH) in Spain
    13.2.4.3. Market Sales of Pulmonary Arterial Hypertension (PAH) by Products in Spain
    13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
    13.2.5. United Kingdom
    13.2.5.1. Market Size of Pulmonary Arterial Hypertension (PAH) in United Kingdom
    13.2.5.2. Percentage Share of drugs marketed for Pulmonary Arterial Hypertension (PAH) in United Kingdom
    13.2.5.3. Market Sales of Pulmonary Arterial Hypertension (PAH) by Products in United Kingdom
    13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
    13.3. Japan
    13.3.1. Market Size of Pulmonary Arterial Hypertension (PAH) in Japan
    13.3.2. Percentage Share of drugs marketed for Pulmonary Arterial Hypertension (PAH) in Japan
    13.3.3. Market Sales of Pulmonary Arterial Hypertension (PAH) by Products in Japan
    13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
    14. Market Drivers
    15. Market Barriers
    16. Appendix
    17. Report Methodology
    17.1. Sources
    18. DelveInsight Capabilities
    19. Disclaimer
    20. About DelveInsight

    *Indication Specific
    Table 1: Total Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in 7MM
    Table 2: Total Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in 7MM by Countries
    Table 3: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in United States (2016-2027)
    Table 4: Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) in United States (2016-2027)
    Table 5: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in United States (2016-2027)
    Table 6: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in United States (2016-2027)
    Table 7: Treatable Cases of the Pulmonary Arterial Hypertension (PAH) in United States (2016-2027)
    Table 8: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in Germany (2016-2027)
    Table 9: Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) in Germany (2016-2027)
    Table 10: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Germany (2016-2027)
    Table 11: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in Germany (2016-2027)
    Table 12: Treatable Cases of the Pulmonary Arterial Hypertension (PAH) in Germany (2016-2027)
    Table 13: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in France (2016-2027)
    Table 14: Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) in France (2016-2027)
    Table 15: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in France (2016-2027)
    Table 16: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in France (2016-2027)
    Table 17: Treatable Cases of the Pulmonary Arterial Hypertension (PAH) in France (2016-2027)
    Table 18: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in Italy (2016-2027)
    Table 19: Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) in Italy (2016-2027)
    Table 20: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Italy (2016-2027)
    Table 21: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in Italy (2016-2027)
    Table 22: Treatable Cases of the Pulmonary Arterial Hypertension (PAH) in Italy (2016-2027)
    Table 23: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in Spain (2016-2027)
    Table 24: Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) in Spain (2016-2027)
    Table 25: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Spain (2016-2027)
    Table 26: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in Spain (2016-2027)
    Table 27: Treatable Cases of the Pulmonary Arterial Hypertension (PAH) in Spain (2016-2027)
    Table 28: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in UK (2016-2027)
    Table 29: Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) in UK (2016-2027)
    Table 30: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in UK (2016-2027)
    Table 31: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in UK (2016-2027)
    Table 32: Treatable Cases of the Pulmonary Arterial Hypertension (PAH) in UK (2016-2027)
    Table 33: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in Japan (2016-2027)
    Table 34: Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) in Japan (2016-2027)
    Table 35: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Japan (2016-2027)
    Table 36: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in Japan (2016-2027)
    Table 37: Treatable Cases of the Pulmonary Arterial Hypertension (PAH) in Japan (2016-2027)
    Table 38: Marketed Therapies
    Table 39: Emerging Therapies
    Table 40: Key Cross Competition
    Table 41:7MM- Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM (2016-2027)
    Table 42:7MM- Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2027)
    Table 43:7MM- Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2027)
    Table 44: United States-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM (2016-2027)
    Table 45: United States-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2027)
    Table 46: United States-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2027)
    Table 47: Germany-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM (2016-2027)
    Table 48: Germany-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2027)
    Table 49: Germany-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2027)
    Table 50: France-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM (2016-2027)
    Table 51: France-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2027)
    Table 52: France-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2027)
    Table 53: Italy-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM (2016-2027)
    Table 54: Italy-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2027)
    Table 55: Italy-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2027)
    Table 56: Spain-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM (2016-2027)
    Table 57: Spain-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2027)
    Table 58: Spain-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2027)
    Table 59:UK-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM (2016-2027)
    Table 60:UK-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2027)
    Table 61:UK-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2027)
    Table 62: Japan-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM (2016-2027)
    Table 63: Japan-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2027)
    Table 64: Japan-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2027)
    Figure 1: Total Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in 7MM
    Figure 2: Total Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in 7MM by Countries
    Figure 3: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in United States (2016-2027)
    Figure 4: Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) in United States (2016-2027)
    Figure 5: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in United States (2016-2027)
    Figure 6: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in United States (2016-2027)
    Figure 7: Treatable Cases of the Pulmonary Arterial Hypertension (PAH) in United States (2016-2027)
    Figure 8: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in Germany (2016-2027)
    Figure 9: Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) in Germany (2016-2027)
    Figure 10: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Germany (2016-2027)
    Figure 11: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in Germany (2016-2027)
    Figure 12: Treatable Cases of the Pulmonary Arterial Hypertension (PAH) in Germany (2016-2027)
    Figure 13: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in France (2016-2027)
    Figure 14: Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) in France (2016-2027)
    Figure 15: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in France (2016-2027)
    Figure 16: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in France (2016-2027)
    Figure 17: Treatable Cases of the Pulmonary Arterial Hypertension (PAH) in France (2016-2027)
    Figure 18: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in Italy (2016-2027)
    Figure 19: Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) in Italy (2016-2027)
    Figure 20: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Italy (2016-2027)
    Figure 21: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in Italy (2016-2027)
    Figure 22: Treatable Cases of the Pulmonary Arterial Hypertension (PAH) in Italy (2016-2027)
    Figure 23: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in Spain (2016-2027)
    Figure 24: Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) in Spain (2016-2027)
    Figure 25: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Spain (2016-2027)
    Figure 26: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in Spain (2016-2027)
    Figure 27: Treatable Cases of the Pulmonary Arterial Hypertension (PAH) in Spain (2016-2027)
    Figure 28: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in UK (2016-2027)
    Figure 29: Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) in UK (2016-2027)
    Figure 30: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in UK (2016-2027)
    Figure 31: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in UK (2016-2027)
    Figure 32: Treatable Cases of the Pulmonary Arterial Hypertension (PAH) in UK (2016-2027)
    Figure 33: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in Japan (2016-2027)
    Figure 34: Sub-Type Specific cases of the Pulmonary Arterial Hypertension (PAH) in Japan (2016-2027)
    Figure 35: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Japan (2016-2027)
    Figure 36: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in Japan (2016-2027)
    Figure 37: Treatable Cases of the Pulmonary Arterial Hypertension (PAH) in Japan (2016-2027)
    Figure 38: Marketed Therapies
    Figure 39: Emerging Therapies
    Figure 40: Key Cross Competition
    Figure 41:7MM- Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM (2016-2027)
    Figure 42:7MM- Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2027)
    Figure 43:7MM- Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2027)
    Figure 44: United States-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM (2016-2027)
    Figure 45: United States-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2027)
    Figure 46: United States-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2027)
    Figure 47: Germany-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM (2016-2027)
    Figure 48: Germany-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2027)
    Figure 49: Germany-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2027)
    Figure 50: France-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM (2016-2027)
    Figure 51: France-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2027)
    Figure 52: France-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2027)
    Figure 53: Italy-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM (2016-2027)
    Figure 54: Italy-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2027)
    Figure 55: Italy-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2027)
    Figure 56: Spain-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM (2016-2027)
    Figure 57: Spain-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2027)
    Figure 58: Spain-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2027)
    Figure 59:UK-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM (2016-2027)
    Figure 60:UK-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2027)
    Figure 61:UK-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2027)
    Figure 62: Japan-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM (2016-2027)
    Figure 63: Japan-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2027)
    Figure 64: Japan-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM (2016-2027)

    • Single User License
      $6,250.00
    • Site License
      $12,500.00
    • Global License
      $18,750.00

    Why Us?

    Diligent Market mission is to provide "insight across the value chain" to help organizations make important business decisions through the use and analysis of actionable market intelligence. It is our mission to provide the most effective results and services coupled with acute client care to create a long-lasting relationship with our clients.